Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 7Completed 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Colorectal Neoplasms 1

Interventions

Capecitabine 27pembrolizumab 19Oxaliplatin 19Fluorouracil 17Cisplatin 17Trastuzumab 14Docetaxel 14Leucovorin 11Paclitaxel 8Irinotecan 8S 1 (combination) 7Epirubicin 6Cyclophosphamide 5tegafur-gimeracil-oteracil 4aldesleukin 4Hyperthermic Intraperitoneal Chemotherapy 4titanium silicide 3spartalizumab 3fludarabine phosphate 3fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Ramucirumab 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Carboplatin 3Albumin-Bound Paclitaxel 3Ado-Trastuzumab Emtansine 3vistusertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Stomach Neoplasms × trastuzumab deruxtecan × Clear all
NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡